GM-CSF for Reversal of immunopAralysis in pediatriC sEpsis-induced MODS Study
A legfontosabb adatok
- Ki végzi
- Nationwide Children's Hospital
- Hol
- Aurora, Columbus, Detroit, Los Angeles, Philadelphia, Pittsburgh, San Francisco és Washington D.C. (Egyesült Államok)Mind a 8 helyszín megnézése
- Azonosító
- Állapot
- Befejeződött
- Fázis
- 4. fázis
- Résztvevők
- 75 fő vett részt
- Kezdés
- 2018. dec. 5.
- Befejezés
- 2023. dec. 5.
- A vizsgálat típusa
- Beavatkozással járó, 4 csoport
- A vizsgált kezelések
- GM-CSF
- A regiszteradat frissítve
- 2026. május 5.
Ki vehet részt
- Életkor
- Legfeljebb 17 év
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 18 feltétel megnézéseKevesebb
Ki vehet részt
- >= 40 weeks gestational age to <18 years; AND
- Onset of >=2 new organ dysfunctions (compared to pre-sepsis baseline) as measured by the Proulx criteria; AND
- Documented or suspected infection as the MODS inciting event
Ki nem vehet részt
- Renal replacement therapy at the time of screening; OR
- Previous enrollment in the GRACE study
- Active (or planned within 7 days) immunosuppressive treatment for oncologic, transplant, or rheumatologic disease; OR
- Known primary immunodeficiency disorder; OR
- Diagnosis of myeloid leukemia, myelodysplasia, or autoimmune thrombocytopenia;OR
- Known allergy to GM-CSF; OR
- Documented hyperferritinemia (serum ferritin >= 500 ng/ml) during current sepsis event; OR
- Unable to collect a cumulative total of 20.5 mL of blood for this study due to research blood draw limits; OR
- Limitation of care order at the time of screening; OR
- Patients at high risk for brain death; OR
- Contraindication to SQ injection (ECMO); OR
- Burns where >5% of the total body surface area is affected; OR
- On ECMO or anticipated to require ECMO; OR
- Known pregnancy; OR
- Inability to collect and ship sample for immune testing on MODS Day 2; OR
Helyszínek itt: Egyesült Államok
- Children's Hospital of ColoradoAurora, Egyesült Államok
- Nationwide Children's HospitalColumbus, Egyesült Államok
- Children's Hospital of MichiganDetroit, Egyesült Államok
- UCLA Mattel Children's HospitalLos Angeles, Egyesült Államok
- Children's Hospital of PhiladelphiaPhiladelphia, Egyesült Államok
- Children's Hospital of PittsburghPittsburgh, Egyesült Államok
- Benioff Children's Hospital/UCSFSan Francisco, Egyesült Államok
- Children's National Medical CenterWashington D.C., Egyesült Államok
A vizsgálatról
Mit akar kideríteni a vizsgálat
This study is an open-label, multi-center, interventional trial in which children with sepsis-induced MODS undergo surveillance immune function testing beginning on Day 2 of MODS. Those children who demonstrate immunoparalysis (TNF-alpha response <200 pg/ml) will receive a 7-day course of GM-CSF at a dose of 125 or 250 mcg/m2/day by either the intravenous (IV) or subcutaneous (SQ) route.
A teljes eredeti leírásKevesebb
The goal of the study is to establish the dose and route of delivery that results in resolution of immunoparalysis (TNF-alpha response >=200 pg/ml) by the morning after the 3rd scheduled dose with persistent resolution of immunoparalysis on the morning after the 7th scheduled dose. Resolution of immunoparalysis in 8 out of the first 10 subjects in a study treatment arm represents a successful dose and route. The goal of this study will be achieved through the following Specific Aims:
Specific Aim 1. Establish the immunologic efficacy of GM-CSF administered by the IV and SQ routes in children with immunoparalysis in the setting of sepsis-induced MODS.
Specific Aim 2. Estimate the pharmacokinetic parameters by the IV and SQ GM-CSF administered in pediatric sepsis-induced MODS.
Specific Aim 3. Demonstrate the feasibility of screening, enrollment, drug delivery, and sample collection for a multi-center immunostimulation trial in children with sepsis-induced MODS.
A vizsgálat 4 csoportja
- IV GM-CSF 125 mcg/m2/doseA vizsgált kezelés
Subjects in this arm who demonstrate immunoparalysis will receive GM-CSF by the intravenous (IV) route at a dose of 125 mcg/m2/day for 7 consecutive days.
Kezelés: GM-CSF
- SQ GM-CSF 125 mcg/m2/doseA vizsgált kezelés
Subjects in this arm who demonstrate immunoparalysis will receive GM-CSF by the subcutaneous (SQ) route at a dose of 125 mcg/m2/day for 7 consecutive days.
Kezelés: GM-CSF
- IV GM-CSF 250 mcg/m2/doseA vizsgált kezelés
If the IV 125 mcg/m2/dose arm is not successful in the first cohort of subjects, we will transition to 250 mcg/m2/day via the IV route for 7 consecutive days in a subsequent cohort.
Kezelés: GM-CSF
- SQ GM-CSF 250 mcg/m2/doseA vizsgált kezelés
If the SQ 125 mcg/m2/dose arm is not successful in a cohort of subjects (or if the IV dose had to be escalated to 250 mcg/m2/dose), we will transition to 250 mcg/m2/day via the SQ route for 7 consecutive days in a subsequent cohort.
Kezelés: GM-CSF
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- GM-CSF for Reversal of immunopAralysis in pediatriC sEpsis-induced MODS (GRACE)
- A regiszteradat frissítve
- 2026. május 5.